THX-OSA01 for obstructive sleep apnea
Therapix is currently developing THX-OSA01 for the treatment of obstructive sleep apnea (OSA). THX-OSA01 combines tetrahydrocannabinol (THC), the active constituent of cannabis, and palmitoylethanolamide (PEA), a generally regarded as safe (GRAS) lipid with cannabinoid properties. The company recently initiated a Phase IIa program to evaluate the efficacy of THX-OSA01 in 30 patients with confirmed OSA. The primary efficacy endpoint is a significant decrease in AHI after treatment.
OSA is a chronic sleep disorder characterized by recurring episodes of partial (hypopnea: decrease in air flow lasting 10 seconds or more with 30% oxygen reduction) or complete (apnea: cessation of air flow for 10 seconds or more) obstruction of airway passages during sleep causing respiratory-related arousals. OSA occurs when the throat muscles that support the soft palate, uvula, tonsils, side walls of the throat and tongue relax during sleep causing the airway to narrow or close. Signs and symptoms of OSA include daytime fatigue, difficulty concentrating, morning headaches, mood swings and depression, loud snoring, sudden arousals from sleep due to gasping or choking, and high blood pressure. Additionally, OSA is associated with several comorbidities including hypertension, congestive heart failure, obesity and diabetes.
The gold standard diagnostic test for OSA is an overnight polysomnogram, or sleep study, which involves the simultaneous recording of physiologic signals including brain activity, muscle tissue activity, eye movement, breathing patterns and blood-oxygen levels. OSA severity is measured quantitatively using the Apnea-Hypopnea Index (AHI), or the average number of breathing disturbances per one hour of sleep in addition to average oxyhemoglobin desaturation and frequency of arousals from sleep. AHI scores of 0-4, 5-14, 15-30, and >30 correspond to normal, mild, moderate, and severe sleep apnea, respectively.
An estimated 5.9 million adults in the US are diagnosed with OSA while only 54% of those patients diagnosed are actively treated for the condition. Studies suggest that approximately 75% to 80% of severe cases remain undiagnosed, which leads to some variance in estimates of OSA disease prevalence. In addition, the prevalence of OSA is expected to rise along with the ageing population and obesity epidemic. Prevalence estimates from Europe, Australia and Asia are comparable to that of the US.
Treatment options for OSA
Primary treatment options for OSA include positive airway pressure (PAP) devices, oral appliances, and surgery. PAP devices moderately blow pressurized air through the airway at a pressure high enough to keep the throat open and can be delivered through three modes including continuous (CPAP), bilevel (BPAP), and autotitrating (APAP). CPAP is the most effective therapy and has shown to improve quality of life; however, approximately 8.2% to 9.2% of newly diagnosed patients refuse CPAP therapy and compliance rates range from 67% to 96%. Oral appliances are recommended to those who are either unable to tolerate CPAP therapy or refuse it. According to the American Sleep Apnea Association, over 100 different devices are FDA approved for the treatment of snoring and OSA. The devices are designed to hold the lower jaw forward to keep the airway open and prevent the tongue and upper airway muscles from collapsing. Efficacy of oral appliance therapy is 52%. Surgical treatment includes a variety of upper airway reconstructive or bypass procedures such as a tonsillectomy and/or adenoidectomy, tongue reduction or stabilization, nasal valve surgery and tracheotomy. Adjunctive to first-line therapies, weight loss, positional therapy and supplemental oxygen are also recommended to relieve symptoms of OSA.
A number of pharmacotherapies have been investigated for OSA management. However, no pharmacologic agent has demonstrated comparable efficacy to PAP. This is a difficult indication to drug because of the multifaceted nature of the neurochemical control and neuromodulation of the central respiratory drive and upper airway motor output. Drugs used to supplement OSA treatment target the reduction or modification of OSA risk factors (nasal congestion, reduced estrogen/testosterone levels), underlying metabolic diseases (thyroid disease, obesity), daytime sleepiness, hypertension and lipid disorders. According to clinical guidelines for the management of OSA in adults, the use of several pharmacotherapies such as methylxanthine derivatives, selective serotonergic reuptake inhibitors (SSRIs), protriptyline and estrogen therapy are generally not recommended for treatment (Exhibit 1). Furthermore, short-acting nasal decongestant sprays do not improve OSA and are not recommended due to concerns with rebound nasal congestion brought about by chronic use. Adjunct topical nasal corticosteroids have been shown to decrease AHI in patients with OSA. There is significant opportunity in this space for a product that can effectively manipulate the respiratory control system to improve OSA.
Exhibit 1: Brief summary of ineffective pharmacologic treatment for OSA
Drug |
Notes |
Recommendation |
Methylxanthine derivatives |
Stimulate ventilation by blocking adenosine receptors. IV aminophylline and theophylline studies showed no significant change in AHI, worsening of sleep quality and efficiency. |
No. |
Opioid antagonists |
Stimulate ventilation by blocking endorphins that inhibit respiration or stimulating the cortex. Naloxone study did not improve AHI, minimally reduced oxygen desaturation index, and decreased total sleep time. |
No. |
Doxapram |
Stimulates chemoreceptors of carotid arteries to stimulate respiration. Doxapram study improved blood-oxygen desaturation, decreased apnea length, but did not decrease the frequency of apneas. |
No. |
Nicotinic agents |
Nicotinic acetylcholine receptor modulates excitatory inputs to hypoglossal motor neurons (extrinsic and intrinsic muscles of the tongue) and increases diaphragm activity. Studies have shown reduced sleep efficiency, impaired sleep, and variable AHI reduction. |
No. |
Carbonic anhydrase inhibitor |
Stimulates ventilation by inducing metabolic acidosis. Acetazolamide studies showed decreases in AHI, excessive daytime fatigue, and frequent side effects such as burning/tingling sensations, ringing in the ears, nausea, etc. |
No. |
Paroxetine |
SSRI agent to regulate upper airway dilator muscles. Studies showed reduction in AHI during NREM sleep, but not during REM sleep. No improvement in daytime fatigue, morning headaches, depression, or concentration. |
No. |
Protriptyline |
TCA to reduce apnea episodes and increase daytime alertness. Studies have shown mixed results. Two studies showed no AHI or blood-oxygen level improvement. Another study showed reduced AHI during NREM sleep, improved oxygen desaturation and anticholinergic side effects. |
No. |
Clonidine |
Stimulates alpha-adrenoceptors, which reduces sympathetic outflow from the central nervous system, decreases peripheral resistance, renal vascular resistance, heart rate and blood pressure. Studies showed complete REM sleep suppression and reduced time spent in REM sleep. In studies with OSA patients undergoing surgery, an opioid sparing effect was found. |
Not for primary treatment, potential for perioperative management. |
Mirtazapine |
Enhances central respiratory drive by the de-inhibition of the vagal nucleus solitary input. Studies have shown mirtazapine increases sleep continuity and reduces AHI. Side effects include weight gain and increased sedation effects. |
No. |
Physostigmine |
Increases sympathetic autonomic activity. Study demonstrated reduction in AHI during REM sleep. More studies are needed. |
Potential for REM-related OSA. |
Estrogen and progesterone |
Enhance respiratory chemo-sensitivity. Two studies using both estrogen and progesterone showed decreased AHI and shorter hypopneas. In another study, estrogen alone reduced AHI, and progesterone weakened the effects. A progesterone study did not show any AHI improvement. Several risks are associated with hormone replacement therapy including venous thromboembolism, ischemic stroke and breast cancer. |
No. |
Thyroid replacement |
Hypothyroid treatment has ambiguous effects on OSA. |
Adjuvant to CPAP. |
Source: Adopted from Abad, V., & Guilleminault, C. (2011). Note: SSRI = selective serotonin reuptake inhibitor, NREM = Non-REM, TCA = tricyclic antidepressant.
THC as a vagal afferent modulator for OSA
Several studies have highlighted the role of endocannabinoids as a neuromodulator of cardio-respiratory functions as well as interactions with neurotransmitters related to sleep-wake behaviors. Comparable factors have been shown in animal studies demonstrating respiratory stability improvement with cannabinoid agonists. Increased activity of vagus nerves, peripheral components of respiratory control including respiratory frequency, reduces upper airway activation or openness and therefore may predispose an individual to OSA. The nodose ganglia of the vagus nerves contain receptors for neurochemicals that can modulate vagal afferent activity. Studies have shown that vagal afferent nerves are inhibited by the injection of dronabinol, a non-selective cannabinoid (CB) 1 and CB2 agonist, into the nodose ganglia and the attenuation of nerve activity causes an increase in upper airway activity.
Two small-scale, randomized controlled clinical studies have been performed by RespireRx Pharmaceuticals examining THC for the treatment of obstructive sleep apnea. The company licensed exclusive worldwide rights to develop and commercialize cannabinoids for the treatment of breathing-related sleep disorders from the University of Illinois at Chicago. The first study was a 21-day randomized, placebo controlled, dose escalation (2.5mg, 5mg, 10mg) Phase IIa trial of dronabinol (generic THC) in 22 patients with OSA and it showed a significant decrease (32%) in AHI (events/hour) compared to baseline. 2.5mg (p= 0.007) and 10mg (p=0.036) doses of dronabinol significantly reduced AHI scores compared to baseline. The second study examined 56 patients with moderate to severe OSA in placebo and dose escalation cohorts (2.5mg and 10mg of dronabinol per day at night) over six weeks. It reached similar results, showing significant improvement in AHI scores at 2.5mg (p<0.02) and 10mg (p<0.001) and overall patient satisfaction (10mg, p<0.02). THC caused mild side effects including dry mouth, fatigue, headache, increased appetite, dizziness and sleepiness. RespireRx’s dronabinol for OSA program is Phase III ready.
Unlike previous attempts at targeting OSA using THC, Therapix’s THX-OSA01 is a co-formulation of THC with PEA, a lipid amide present in food that shares significant structural similarity to endocannabinoids. PEA has been approved for use as a health supplement in some parts of Europe and Canada because small-scale clinical studies, as well as case studies, indicate some benefit for the treatment of chronic inflammation and chronic pain, as well as little to no side effects. The Phase IIa trial will investigate doses up to 10mg THC and 800mg PEA. According to the company, the trial will cost approximately $0.5m and it expects a readout by mid-2018. Therapix believes that the “entourage effect” will enable PEA to enhance the potency of THC and improve its formulation’s overall efficacy, although this is by no means guaranteed.
In parallel, Therapix entered into a product development agreement with Cure Pharmaceutical, a US drug delivery company, to develop a THC/PEA formulation on Cure’s buccal multilayer oral thin film (OTF), called CureFilm, to determine the most effective drug delivery mechanism for the THC/PEA formulation in an effort to increase drug bioavailability and half-life as well as stimulate rapid onset. Cure is developing a combination of 2.5mg of THS with 200mg PEA on its OTF technology.